Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of HSCO.

New AI Tool Predicts Whether Aggressive Small Cell Lung Cancer Will Respond to Treatment

March 31, 2026

Roswell Park Comprehensive Cancer Center

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

Rising Rates, Screening Gaps, and Emerging Therapeutic Targets in CRC: Your Key Clinical Questions Answered

March 31, 2026

Courtney Flaherty

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

AI Tools Could Drive Improved Risk Stratification, Treatment Decision-Making in Multiple Myeloma

March 31, 2026

Chris Ryan

C. Ola Landgren, MD, PhD, discusses the development of the AI risk-stratification model CORAL and its potential role in individualizing myeloma care.

EMPOWER-Lung3 Analysis Reveals Differential Outcomes With Cemiplimab/Chemo in Genomic Subsets of NSCLC

March 30, 2026

Kyle Doherty

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Adjuvant Treatment Advances Improve Outcomes in Kidney Cancer but Unmet Needs Persist

March 30, 2026

Kyle Doherty

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

CHMP Recommends Approval of First-Line Lurbinectedin Plus Atezolizumab Maintenance for ES-SCLC

March 30, 2026

Ashling Wahner

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

FDA Grants Priority Review to Lirafugratinib for FGFR2+ Pretreated Cholangiocarcinoma

March 30, 2026

Courtney Flaherty

An NDA for lirafugratinib in pretreated, FGFR2-altered cholangiocarcinoma was accepted for FDA review and assigned a PDUFA date of September 27, 2026.

Lung Cancer Patients Can Safely Receive Half the Usual Radiation Dose — in Just One Treatment

March 30, 2026

Roswell Park Comprehensive Cancer Center

6-year Roswell Park study shows shorter, lower-dose approach works just as well as longer course of treatment

Denosumab-Adet Gains FDA Approval for All Indications of Denosumab

March 30, 2026

Kyle Doherty

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

New TKI Formulations Engender New Horizons for CML Treatment Possibilities

March 30, 2026

Riley Kandel

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

March’s GI Monthly Rewind: Diagnostic Developments and FDA Alignments You Need to Know

March 30, 2026

Courtney Flaherty

We recap the top regulatory decisions of March in GI malignancies.

Erda-iDRS Is Safe and Active in FGFR-Altered NMIBC

March 29, 2026

Kyle Doherty

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

Five Under 5: Top Oncology Videos for the Week of 3/22

March 29, 2026

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

Novel Enzalutamide Delivery Implant Is Safe and Active in Early-Stage Prostate Cancer

March 28, 2026

Kyle Doherty

Enolen was safe and feasible for the treatment of patients with early-stage prostate cancer.

The OncFive: Top Oncology Articles for the Week of 3/22

March 28, 2026

OncLive Staff

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.